Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20729Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lazaridis, G. | en |
| dc.contributor.author | Pentheroudakis, G. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:09:39Z | - |
| dc.date.available | 2015-11-24T19:09:39Z | - |
| dc.identifier.issn | 1040-8428 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20729 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antibodies, Monoclonal/*therapeutic use | en |
| dc.subject | Antibodies, Monoclonal, Humanized | en |
| dc.subject | Antineoplastic Agents/*therapeutic use | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | en |
| dc.subject | Breast Neoplasms/chemistry/*drug therapy | en |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Drug Synergism | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Neoadjuvant Therapy | en |
| dc.subject | Receptor, erbB-2/analysis | en |
| dc.title | Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.critrevonc.2007.07.002 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17766143 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S1040842807001576/1-s2.0-S1040842807001576-main.pdf?_tid=5a63ecbd6f0bc3a8a7cd2749281bd4da&acdnat=1333954257_8b29b9c8fb8c15ebe76a65cb676411cb | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or breast-conserving. Moreover, it offers promise to serve as an in vivo chemosensitivity assay and as a powerful predictive factor for outcome. Trastuzumab, a monoclonal antibody targeting an epitope in the extracellular domain of the Human Epidermal Growth Factor Receptor-2 (HER2/erbB-2), was found to be active in HER2-overexpressing metastatic as well as in resected breast cancer when given post-operatively. In this review, we summarise the evidence on the activity and safety of trastuzumab-containing neoadjuvant chemotherapy for the management of women with localised, irresectable or resectable breast cancer. Twenty-three published studies enrolling a total of 585 patients reported pathologic complete responses (pCR) ranging from 7 to 78% with a favourable adverse event profile, data that are presented and discussed in this review. The impact of trastuzumab on long-term outcome, the identification of surrogate biomarkers for sensitivity or resistance to antineoplastic therapy, the optimal schedule of trastuzumab administration and the more active chemotherapeutic regimen for synergism are only a few of the key points needing elucidation so as to rationalise trastuzumab-based approaches. | en |
| heal.journalName | Crit Rev Oncol Hematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Lazaridis-2008-Integrating trastuzu.pdf | 161.07 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
